225 related articles for article (PubMed ID: 21282952)
41. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
Koschny R; Gotthardt D; Koehler C; Jaeger D; Stremmel W; Ganten TM
Oncology; 2013; 84(1):6-13. PubMed ID: 23075905
[TBL] [Abstract][Full Text] [Related]
42. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
43. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
Curtit E; Thiery-Vuillemin A; Nguyen T; Heyd B; Pivot X; Di Martino V; Borg C
J Clin Oncol; 2011 Apr; 29(12):e330-2. PubMed ID: 21263091
[No Abstract] [Full Text] [Related]
44. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
Spira D; Fenchel M; Lauer UM; Claussen CD; Gregor M; Bitzer M; Horger M
Acad Radiol; 2011 Jan; 18(1):89-96. PubMed ID: 20926315
[TBL] [Abstract][Full Text] [Related]
45. Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma.
Kim JE; Ryoo BY; Ryu MH; Chang HM; Suh DJ; Lee HC; Lim YS; Kim KM; Kang YK
Oncology; 2012; 82(2):119-25. PubMed ID: 22354124
[TBL] [Abstract][Full Text] [Related]
46. Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib.
Lynch MC; Straub R; Adams DR
J Drugs Dermatol; 2011 Mar; 10(3):308-10. PubMed ID: 21369650
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
Kuzuya T; Tsuchiya K; Izumi N
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1883-86. PubMed ID: 21069944
[No Abstract] [Full Text] [Related]
48. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
Lee JH; Chung YH; Kim JA; Shim JH; Lee D; Lee HC; Shin ES; Yoon JH; Kim BI; Bae SH; Koh KC; Park NH
Cancer; 2013 Jan; 119(1):136-42. PubMed ID: 22736425
[TBL] [Abstract][Full Text] [Related]
49. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?
Vitale A; Boccagni P; Kertusha X; Zanus G; D'Amico F; Lodo E; Pastorelli D; Ramirez Morales R; Lombardi G; Senzolo M; Burra P; Cillo U
Transplant Proc; 2012 Sep; 44(7):1989-91. PubMed ID: 22974889
[TBL] [Abstract][Full Text] [Related]
50. Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma.
Lapecorella M; Napolitano M; Tudini M; Bruera G; Lucchesi A; Giordano AV; Mariani G; Ricevuto E
Haemophilia; 2010 Jan; 16(1):185-7. PubMed ID: 19804385
[No Abstract] [Full Text] [Related]
51. A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma.
Balsom SM; Li X; Trolli E; Rose J; Bloomston M; Patel T; Bekaii-Saab TS
Oncology; 2010; 78(3-4):210-2. PubMed ID: 20424492
[TBL] [Abstract][Full Text] [Related]
52. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
53. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
Zhu AX
Expert Opin Investig Drugs; 2010 May; 19(5):663-72. PubMed ID: 20367287
[TBL] [Abstract][Full Text] [Related]
54. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
Zhu AX; Clark JW
Oncologist; 2009 Jan; 14(1):67-9. PubMed ID: 19147690
[No Abstract] [Full Text] [Related]
55. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Kudo M; Ueshima K
Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
[TBL] [Abstract][Full Text] [Related]
56. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
Personeni N; Bozzarelli S; Pressiani T; Rimassa L; Tronconi MC; Sclafani F; Carnaghi C; Pedicini V; Giordano L; Santoro A
J Hepatol; 2012 Jul; 57(1):101-7. PubMed ID: 22414760
[TBL] [Abstract][Full Text] [Related]
57. Current problems with systemic treatment of advanced hepatocellular cancer.
He AR; Soe K; El Zouhairi M
Curr Probl Cancer; 2010; 34(2):131-49. PubMed ID: 20417353
[No Abstract] [Full Text] [Related]
58. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
Kim R; Byrne MT; Tan A; Aucejo F
Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
[TBL] [Abstract][Full Text] [Related]
59. Sorafenib: new indication. For some patients with liver cancer.
Prescrire Int; 2009 Apr; 18(100):59. PubMed ID: 19585718
[TBL] [Abstract][Full Text] [Related]
60. Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event management.
Schott E; Ebert MP; Trojan J
Z Gastroenterol; 2012 Sep; 50(9):1018-27. PubMed ID: 22965633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
